A human model of AD has shown that over-expression of transthyretin supresses Aβ plaque formation, putatively through sequestration [34], while pre-clinical AD models suggest a causal pathway connecting decreased dietary ω6:ω3 ratios with increased PPAR signalling and improved cognitive measures [35, 36]. Here, PPARA is linked to Alzheimer disease.